A Smart Loan Deal for a Biotech Company

In a strategic financial move, a small French eye-care firm has secured a €6 million credit line—not from a bank, but from a long-time shareholder. The arrangement comes with a unique condition: if the company ever withdraws the full amount, the lender could gain nearly 15% ownership of the business—a significant stake.

Flexibility Over Urgency

The €6 million remains on standby for three years, with no obligation to withdraw funds. If the company taps into the line of credit, repayment can be made in cash or newly issued shares. Opting for shares keeps capital within the business but dilutes existing shareholders’ equity.

Why This Move?

The company, which expects strong cash flow from its flagship drug NCX 470—currently in late-stage testing—anticipates surpluses well beyond 2027. With a potential U.S. market launch this summer, approval could mean steady revenue for years.

Still, additional liquidity provides strategic advantages: ✔ Funding new research & development ✔ Acquiring smaller firms ✔ Strengthening negotiation power

The Lender’s Terms

The standby credit comes from Vester Finance, a shareholder with deep industry knowledge. The annual interest rate is set at 7%—but only if the company repays in cash.

The Trade-Off: Ownership vs. Growth

The biggest risk? Share dilution. Existing investors could see their stake shrink—from 1% to less than 0.7%—if the company issues new shares. Management has assured stakeholders that this won’t disrupt the company’s leadership or operations.

Is this a smart play? Only time will tell—but for now, the company has secured a financial cushion without immediate pressure.